These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1951080)

  • 1. Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy.
    Feldman AM; Baughman KL; Lee WK; Gottlieb SH; Weiss JL; Becker LC; Strobeck JE
    Am J Cardiol; 1991 Nov; 68(11):1203-10. PubMed ID: 1951080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.
    Feldman AM; Becker LC; Llewellyn MP; Baughman KL
    Am Heart J; 1988 Sep; 116(3):771-7. PubMed ID: 3046278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Oct; 36(10):1125-31. PubMed ID: 3247528
    [No Abstract]   [Full Text] [Related]  

  • 4. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.
    Cardiovasc Drugs Ther; 1990 Apr; 4(2):419-25. PubMed ID: 2285626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure.
    Sasayama S; Inoue M; Asanoi H; Kodama K; Hori M; Sakurai T; Kawai C
    Heart Vessels; 1986; 2(1):23-8. PubMed ID: 3722083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPC-8212 in the treatment of congestive heart failure: results of a pilot study.
    Kubo SH; Rector TS; Strobeck JE; Cohn JN
    Cardiovasc Drugs Ther; 1988 Dec; 2(5):653-60. PubMed ID: 3154640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity.
    Inoue M; Kim BH; Hori M; Tsuneoka Y; Matsubara N; Kamada T; Kodama K; Naka M; Nanto S; Higashino Y
    Heart Vessels; 1986; 2(3):166-71. PubMed ID: 3793669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
    Feldman AM; Bristow MR; Parmley WW; Carson PE; Pepine CJ; Gilbert EM; Strobeck JE; Hendrix GH; Powers ER; Bain RP
    N Engl J Med; 1993 Jul; 329(3):149-55. PubMed ID: 8515787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.
    Inoue M; Hori M; Yasuda H; Takishima T; Sugimoto T; Sasayama S; Sakurai T; Nonogi H; Kodama K; Kusukawa R
    Cardiovasc Drugs Ther; 1987 Aug; 1(2):169-75. PubMed ID: 3154320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained inotropic effects of a new cardiotonic agent. OPC-8212 in patients with chronic heart failure.
    Asanoi H; Sasayama S; Kameyama T; Ishizaka S; Iuchi K
    Clin Cardiol; 1989 Mar; 12(3):133-8. PubMed ID: 2647327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and arrhythmias].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    J Cardiol; 1990; 20(3):755-65. PubMed ID: 2151866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
    Cohn JN; Goldstein SO; Greenberg BH; Lorell BH; Bourge RC; Jaski BE; Gottlieb SO; McGrew F; DeMets DL; White BG
    N Engl J Med; 1998 Dec; 339(25):1810-6. PubMed ID: 9854116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Zeng XH; Zeng XJ; Li YY
    Am J Cardiol; 2003 Jul; 92(2):173-6. PubMed ID: 12860219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure.
    Asanoi H; Sasayama S; Iuchi K; Kameyama T
    J Am Coll Cardiol; 1987 Apr; 9(4):865-71. PubMed ID: 3558984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy.
    Tyni-Lenné R; Gordon A; Jansson E; Bermann G; Sylvén C
    Am J Cardiol; 1997 Oct; 80(8):1025-9. PubMed ID: 9352972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study.
    G Ital Cardiol; 1989 Jan; 19(1):71-80. PubMed ID: 2663585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
    Ramires FJ; Mansur A; Coelho O; Maranhão M; Gruppi CJ; Mady C; Ramires JA
    Am J Cardiol; 2000 May; 85(10):1207-11. PubMed ID: 10802002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure. Time- and dose-dependence analysis based on pressure-volume relations.
    Feldman MD; Pak PH; Wu CC; Haber HL; Heesch CM; Bergin JD; Powers ER; Cowart TD; Johnson W; Feldman AM; Kass DA
    Circulation; 1996 Feb; 93(3):474-83. PubMed ID: 8565164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
    Kass DA; Van Anden E; Becker LC; Kasper EK; White WB; Feldman AM
    Am J Cardiol; 1996 Sep; 78(6):652-6. PubMed ID: 8831399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.